Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Stock Rating Upgraded by Zacks Research

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was upgraded by Zacks Research from a “hold” rating to a “strong-buy” rating in a report released on Tuesday,Zacks.com reports.

Other research analysts also recently issued research reports about the stock. JPMorgan Chase & Co. raised shares of Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research note on Monday, December 8th. Barclays upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 6th. Finally, Morgan Stanley upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, December 3rd. Three investment analysts have rated the stock with a Strong Buy rating and four have issued a Buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Trading Up 2.3%

Shares of Bayer Aktiengesellschaft stock opened at $12.80 on Tuesday. Bayer Aktiengesellschaft has a fifty-two week low of $5.30 and a fifty-two week high of $13.00. The business’s fifty day moving average is $10.27 and its two-hundred day moving average is $8.80. The company has a quick ratio of 0.71, a current ratio of 1.14 and a debt-to-equity ratio of 1.10. The firm has a market cap of $49.16 billion, a PE ratio of -142.21, a P/E/G ratio of 4.74 and a beta of 0.66.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.